Luliconazole is a new antifungal that was primarily used for the treatment of dermatophytosis. Some studies have shown that it has excellent efficacy against Aspergillus and Candida species, in vitro.

A new study published in Medial Microbiology and Immunology evaluated the activity of luliconazole against some Fusarium species complex isolates.

This study tested 47 isolates of Fusarium against several antifungals including luliconazole. All species were identified using morphology features and PCR sequencing, and antifungal susceptibility were performed according to CLSIM38 A3 guideline.

The results showed that luliconazole has a very low minimum inhibitory concentration value (0.0078-1 µg/ml) in comparison with other tested antifungals. Amphotericin B had a poor effect with a high MIC90 (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml)and itraconazole (4 µg/ml).

The findings of this studyindicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.

Source: Medical Microbiology and Immunology. 2020 Oct;209(5):603-612.doi: 10.1007/s00430-020-00672-4.